查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2094561

癌症和腫瘤分析市場—2026-2032年全球市場預測

Cancer/Tumor Profiling Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，癌症和腫瘤分析市場將成長至 228 億美元，複合年成長率為 9.07%。

主要市場統計數據
基準年 2025 124.1億美元
預計年份：2026年 135.2億美元
預測年份 2032 228億美元
複合年成長率 (%) 9.07%

癌症和腫瘤分析執行摘要

癌症和腫瘤譜分析已成為精準腫瘤學的核心，使臨床醫生、實驗室、保險公司和研究人員能夠透過基因組、轉錄組、蛋白質組、表觀遺傳學和免疫學生物標記來表徵惡性腫瘤。此領域支持治療方案的選擇、臨床試驗入組合格、遺傳風險評估、抗藥性監測、微量殘存疾病評估以及伴隨診斷的開發。國際癌症登記處記錄的全球癌症負擔日益加重、次世代定序的普及、基於生物標記的藥物適應症的擴展以及液態生物檢體在微創腫瘤評估中的日益普及，都推動了這一領域的需求。來自腫瘤學和病理學組織的權威指南持續強調分子檢驗在肺癌、乳癌、結直腸癌、卵巢癌、前列腺癌、黑色素瘤和骨髓惡性腫瘤中的臨床價值。同時，相關人員必須應對諸多挑戰，例如檢體品質要求、保險報銷差異、資料隱私義務、檢測方法的檢驗標準以及公平取得檢測資源的需求。策略重點正從孤立的單基因檢測轉向整合病理學、分子診斷、生物資訊學、電子健康記錄健康記錄和多學科治療決策的綜合癌症分析工作流程。

癌症譜分析領域的變革性變化

在癌症/腫瘤譜分析領域，正經歷著從被動診斷到基於生物標記的預防性治療的結構性轉變。儘管傳統病理學仍然至關重要，但其作用正日益得到綜合基因組分析、多重免疫組化、循環腫瘤DNA分析、RNA融合基因檢測、腫瘤突變負荷評估、微衛星不穩定性檢測以及同源重組缺陷評估等技術的補充。不斷成長的臨床證據支持了這一轉變，尤其是在非小細胞肺癌、乳癌、結直腸癌、惡性黑色素瘤、卵巢癌和某些血液系統惡性腫瘤中，這些證據表明，具有治療意義的突變可以指導標靶治療和免疫療法的決策。另一個顯著的轉變是從僅依賴組織樣本的工作流程轉向組織和液態生物檢體相結合的策略。當組織樣本不足、無法重複切片檢查或需要即時監測抗藥性時，這種轉變尤其明顯。在檢查室中，分子檢測報告正從各部門各自獨立的報告轉向具有明確證據等級、便於臨床解讀的結果，這些結果能夠為腫瘤會診和治療路徑提供支持。儘管伴隨診斷的分析有效性、臨床有效性、檢查室品管系統、數據安全以及療效聲明等方面的監管要求日益嚴格，但保險公司也更加嚴格地審查其臨床效用和與治療結果的相關性。這些變化正推動產業朝著標準化報告、互通數據系統、更強力證據的產生以及腫瘤學家、病理學家、實驗室管理人員、生物資訊學家、遺傳諮詢師和醫療保健系統之間更緊密的合作方向發展。

人工智慧對腫瘤分析的累積影響

人工智慧 (AI) 透過提升數據解讀、工作流程效率和多模態決策支持，對癌症/腫瘤分析的整體產生了累積影響。在數位病理學領域，AI 驅動的影像分析正被用於輔助腫瘤檢測、惡性腫瘤分類、免疫標記定量、空間分析和品管，但仍需要專業病理學家進行監督。在分子譜分析中，機器學習技術結合精心整理的知識庫和臨床證據框架，能夠輔助突變優先排序、複雜基因組模式的檢測、拷貝數和結構變異的整合，以及對意義不明突變的解讀。 AI 也透過整合基因組學、轉錄組學、蛋白質組學、放射組學、病理學和臨床結果數據，加速了生物標記的發現。在液態生物檢體中，計算技術正在提高低循環腫瘤 DNA (ctDNA) 含量樣本的訊號檢測準確性，但預分析控制和正交檢驗仍然至關重要。人工智慧最有價值的應用在於將其整合到檢驗的測試工作流程中，從而提高模型效能、偏差評估、可審計性、網路安全措施以及臨床醫生可讀輸出的透明度。產業領導者正日益關注可解釋人工智慧、聯邦分析、隱私保護的資料協作以及符合監管要求的文件。其實際意義不在於取代專家，而是增強腫瘤團隊處理複雜數據、識別臨床相關生物標記、縮短檢測結果獲取時間以及支持個人化癌症治療決策的能力。

癌症譜分析在全球應用的關鍵區域性見解。

在亞太地區，癌症/腫瘤譜分析在主要癌症中心的應用正在迅速擴展和發展，這得益於該地區較高的癌症發病率、不斷提升的定序能力、國家級精準醫療舉措以及標靶治療的日益普及。日本、中國、韓國、印度和澳洲是主要貢獻者，它們在肺癌生物標記、胃腸道癌症、乳癌、肝癌和液態生物檢體領域進行了積極的研究。歐洲憑藉著統一的臨床指南、高品質的病理網路、國家基因組學計畫以及分子腫瘤學委員會的日益普及，展現出強勁的發展勢頭，儘管西歐、南歐、中歐和東歐各醫療保健系統之間的服務獲取仍然存在差異。北美在癌症譜分析方面仍然非常成熟，擁有完善的分子病理基礎設施、在晚期癌症中廣泛應用的綜合基因組譜分析、強大的臨床試驗網路以及針對特定生物標記檢測的完善的保險報銷機制。美國在拉丁美洲地區引領著基於生物標記的腫瘤學發展，而加拿大則強調省級癌症計畫、檢查室品質標準以及公平取得醫療資源。拉丁美洲的進展並不均衡，巴西和墨西哥在區域性措施中主導，但面臨保險報銷、檢查室分佈、專家資源以及跨境獲取先進檢測等方面的挑戰。非洲尚處於實施初期，癌症譜分析的重點在於都市區專科醫療中心與學術機構之間的合作。關鍵優先事項包括病理診斷能力、檢體運輸系統、人力資源開發、加強癌症登記以及確保獲得價格合理的、經過檢驗的分子診斷服務。在中東，尤其是在高所得的海灣國家，對三級癌症中心、基因組醫學計畫和腫瘤基礎設施的投資正在推進，但由於人力資源短缺和保險報銷差異，全部區域的醫療資源取得仍然受到限制。

癌症/腫瘤分析市場關鍵群體分析

北約成員國與歐洲和北美先進的醫療保健體系高度重合，這些國家的癌症/腫瘤譜分析受到軍事和民用醫學研究、衛生安全優先事項、數據管治以及跨境臨床合作的影響。然而，各成員國的採納程度因資金籌措、保險報銷和檢查室基礎設施而異。在七國集團（G7）國家，由於醫療保健體係成熟、檢查室認證體系完善、臨床研究實力雄厚以及能夠獲得標靶治療和免疫腫瘤療法，生物標記主導的腫瘤學普遍得到廣泛應用。金磚國家（BRICS）構成了一個多元化但具有重要戰略意義的癌症譜分析環境。中國和印度正在擴大大規模定序和腫瘤檢測能力，而巴西和南非則透過參考中心和公私合營的臨床網路來建立服務管道。儘管在服務管道和技術轉移方面有局限性，俄羅斯也保持著專業的腫瘤學和分子診斷能力。歐盟受益於成員國間法規協調、臨床指南採納、資料保護框架建立、標準檢查室網路建構以及對全面癌症診療服務的支持，同時也在持續解決成員國間報銷制度和實施方面的差異。東南亞國協正透過擴大癌症診療基礎設施、創建醫療旅遊中心、促進學術合作以及逐步將分子檢測融入三級醫療，提升其癌症診斷能力，但新加坡、馬來西亞、泰國、印尼、菲律賓和越南在具體實施方面仍存在顯著差異。海灣合作理事會（GCC）國家正崛起為精準腫瘤學領域的領導者，重點關注遺傳性癌症、肺癌、乳癌和人群基因組學，並得到政府對基因組醫學、三級癌症中心和國家衛生轉型策略的投資支持。

主要國家癌症和腫瘤分析趨勢

在中國，癌症/腫瘤基因組分析正在蓬勃發展，這得益於龐大的醫院網路、國內定序能力以及肺癌、胃腸癌、肝癌和乳癌等疾病的高臨床需求。美國是癌症基因組分析領域最先進的國家之一，這得益於次世代定序的廣泛臨床應用、完善的腫瘤學指南、分子腫瘤委員會、伴隨診斷以及大規模的臨床試驗系統。日本擁有系統化的精準腫瘤學環境，包括全面的基因組分析路徑和積極推廣伴隨診斷。在印度，基因組分析在大都會圈癌症中心的應用日益廣泛，其發展與意識提升的提高、檢測服務的擴展以及對經濟高效檢測模式的需求密切相關。德國擁有強大的分子診斷、病理學專業知識和臨床研究能力，並輔以高標準的檢查室檢驗和專業的腫瘤護理。英國擁有先進的國家基因組基礎設施和強大的病理網路，並正在將基因組檢測整合到癌症治療過程中。澳洲結合了高品質的癌症治療、覆蓋全國的研究網路以及在專科中心引入的分子檢測，確保了其地理分散的人口都能公平地獲得醫療服務。法國擁有悠久的分子檢測網路歷史和全國性的癌症控制計劃，支持對主要腫瘤類型進行生物標記檢測。韓國擁有先進的技術環境，強大的醫院精準腫瘤學計畫、定序能力以及支持生物標記主導醫療的數位醫療基礎設施。在義大利和西班牙，主要癌症中心廣泛應用了分子分型，尤其是在肺癌、乳癌、大腸癌、卵巢和黑色素瘤方面，但國家和地區的醫療保險報銷制度影響了檢測的一致性。加拿大建立了完善的癌症醫療機構和省級檢測項目，持續的醫療服務可及性、醫療保險報銷的一致性以及檢查室品質仍然至關重要。俄羅斯擁有專業的癌症醫療機構和分子診斷技術，但醫療服務的可近性可能因地區和醫療資金籌措來源而異。巴西在腫瘤學研究和先進診斷方法的應用方面領先許多拉丁美洲國家，尤其是在私立和學術機構，儘管地區差異仍然顯著。在墨西哥，分子腫瘤學系統正在主要都市區擴展，但成本效益和保險覆蓋範圍限制了其可及性。在西班牙，精準腫瘤學透過專業癌症網路、病理診斷能力以及針對高優先級腫瘤類型的基於指南的生物標記檢測而不斷加強。

為行業領導者提供的實用建議

產業領導者應優先考慮經臨床檢驗的癌症/腫瘤分析解決方案，這些方案應具備分析準確性、可重複性、可操作的報告以及與治療決策的明確相關性。一套完善的策略應包括切片檢查和液態生物檢體的整合工作流程、穩健的預分析管理、快速的周轉時間以及符合已批准癌症報告框架的循證突變解讀。各機構應投資於可互通的數據平台，這些平台能夠連接實驗室資訊系統、病理圖像、基因組數據、電子健康記錄和臨床試驗匹配工具，同時確保隱私、網路安全和知情同意管理。與癌症中心、學術網路、病理學團隊和公共衛生計畫建立合作關係，可以增強證據生成和實際臨床效用。領導者還應透過制定循序漸進的檢測路徑、區域參考檢查室模式、臨床醫生教育計劃以及基於患者預後而非檢測量的保險公司合作策略來解決准入障礙。人工智慧的部署應透過透明的檢驗、偏差監測、人工監督和持續的效能審計進行管理。為了保持競爭力，相關人員應重點關注可擴展的生物資訊學、品管、監管準備、多學科腫瘤委員會支持以及以患者為中心的報告，以幫助腫瘤學家將複雜的生物標記資訊轉化為及時的治療措施。

調查方法

本執行摘要採用結構化的二手研究方法檢驗，使用了經驗證的公共領域和行業認可的資訊來源，包括腫瘤臨床指南、監管出版刊物、同行評審文獻、癌症登記數據、公共衛生機構資源、臨床實驗室醫學標準以及精準腫瘤學政策文件。該研究途徑調查方法強調對臨床實踐建議、診斷技術應用模式、生物標記效用研究、區域醫療基礎設施指標以及公開的國家癌症控制舉措等方面的證據進行三角驗證。研究結果經過檢驗，以避免未經證實的論斷，並排除市場規模估算、預測和公司特定定位。區域、群體和國家層面的評估整合了已記錄的醫療基礎設施、癌症治療成熟度、報銷環境、基因組醫學計劃以及分子診斷在腫瘤學中的應用。分析著重於定性策略情報、臨床相關性、技術轉型和應用障礙，而非收入預測。關鍵主題透過多個可靠資訊來源的一致性得到檢驗，同時考慮到監管環境、檢查室品質標準、臨床效用、資料管治和公平獲取。

結論

癌症/腫瘤譜分析透過將腫瘤的分子和細胞特徵與診斷、預後、治療選擇、抗藥性監測以及臨床試驗入合格聯繫起來，正在重新定義腫瘤學。該領域正從有限的生物標記檢測發展成為一個整合的精準腫瘤學生態系統，結合了組織學分析、液態生物檢體、數位病理學、生物資訊學和人工智慧驅動的解讀。在臨床指南、保險報銷、檢查室品管系統、專家網路和標靶治療可及性協調一致的地區，腫瘤譜分析的應用最為廣泛；而新興地區則繼續優先考慮基礎設施、可負擔性和人才培養。在檢驗、透明度和公平性仍然至關重要的前提下，隨著人工智慧、多模態數據整合和標準化報告的出現，腫瘤譜分析的效用將持續提高。對於醫療保健系統、實驗室和技術提供者而言，最重要的機會在於使癌症譜分析在臨床上可用且擴充性操作，使更多患者能夠在不同的醫療環境中獲得這項服務。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 癌症和腫瘤分析市場：按產品類型分類

  • 耗材和試劑
    • 抗體
    • PCR試劑
    • 探測
    • 定序試劑
  • 裝置
    • 螢光顯微鏡
    • 質譜儀
    • 微陣列掃描儀
    • PCR裝置
    • 序列器
  • 軟體服務
    • 生物資訊軟體
    • 雲端平台
    • 諮詢服務
    • 資料管理系統

第8章 癌症和腫瘤分析市場：按技術分類

  • 螢光雜合反應和細胞遺傳學
  • 免疫組織化學
  • 微陣列技術
  • 次世代定序

第9章 癌症和腫瘤分析市場：按癌症類型分類

  • 瘤
    • 乳癌
    • 肺癌
    • 結腸癌
    • 攝護腺癌
  • 骨髓惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤

第10章 癌症和腫瘤分析市場：按樣本類型分類

  • 組織
  • 血
  • 骨髓

第11章 癌症和腫瘤分析市場：按臨床應用分類

  • 預後
  • 治療方案
  • 監測和監視
    • 治療反應監測
    • 復發監測
    • 微量殘存疾病監測
  • 篩檢和風險評估

第12章 癌症和腫瘤分析市場：按最終用戶分類

  • 診斷檢查室
  • 醫院和診所
  • 製藥和生物製藥公司
  • 研究和學術機構

第13章 癌症和腫瘤分析市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章 癌症與腫瘤分析市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章 癌症和腫瘤分析市場：按國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • 4basecare Onco Solutions Private Limited
  • ACT Genomics Co., Ltd. by Prenetics Global Limited
  • Agendia, Inc.
  • Agilent Technologies, Inc.
  • BostonGene Corporation
  • Caris Life Sciences
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GENINUS Inc.
  • GenScript Biotech Corporation
  • Guardant Health, Inc.
  • Hologic, Inc.
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • IMBdx, Inc.
  • Laboratory Corporation of America Holdings
  • Lucence Health, Inc.
  • Merck KGaA
  • NanoString Technologies, Inc.
  • Neogenomics, Inc.
  • Nonacus Limited
  • OncoDNA SA
  • Oncompass Medicine Hungary Kft.
  • Paragon Genomics, Inc.
  • Personalis, Inc.
  • Perthera, Inc.
  • Predictive Oncology Inc.
  • Strand Life Sciences
  • Sysmex Corporation
  • Takara Bio Inc.
  • Tempus Labs Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-374DB5A06C7F

The Cancer/Tumor Profiling Market is projected to grow by USD 22.80 billion at a CAGR of 9.07% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.41 billion
Estimated Year [2026] USD 13.52 billion
Forecast Year [2032] USD 22.80 billion
CAGR (%) 9.07%

Cancer/Tumor Profiling Executive Summary

Cancer/tumor profiling is becoming central to precision oncology, enabling clinicians, laboratories, payers, and researchers to characterize malignancies through genomic, transcriptomic, proteomic, epigenetic, and immunologic biomarkers. The field supports therapy selection, clinical trial matching, hereditary risk assessment, resistance monitoring, minimal residual disease evaluation, and companion diagnostic development. Demand is being shaped by the rising global cancer burden documented by international cancer registries, wider use of next-generation sequencing, expanded biomarker-driven drug labels, and increasing adoption of liquid biopsy for less invasive tumor assessment. Verified guidance from oncology and pathology organizations continues to reinforce the clinical value of molecular testing in cancers such as lung, breast, colorectal, ovarian, prostate, melanoma, and hematologic malignancies. At the same time, stakeholders must navigate sample quality requirements, reimbursement variability, data privacy obligations, assay validation standards, and the need for equitable access. The strategic priority is shifting from isolated single-gene testing toward integrated cancer profiling workflows that connect pathology, molecular diagnostics, bioinformatics, electronic health records, and multidisciplinary treatment decision-making.

Transformative Shifts in the Cancer Profiling Landscape

The cancer/tumor profiling landscape is undergoing a structural shift from reactive diagnostics to proactive, biomarker-informed care. Traditional pathology remains essential, but it is increasingly complemented by comprehensive genomic profiling, multiplex immunohistochemistry, circulating tumor DNA analysis, RNA fusion testing, tumor mutational burden assessment, microsatellite instability testing, and homologous recombination deficiency evaluation. This transformation is supported by expanding clinical evidence that actionable alterations can guide targeted therapy and immunotherapy decisions, particularly in non-small cell lung cancer, breast cancer, colorectal cancer, melanoma, ovarian cancer, and selected hematologic cancers. Another major shift is the movement from tissue-only workflows toward combined tissue and liquid biopsy strategies, especially when tissue is insufficient, repeat biopsies are impractical, or real-time resistance monitoring is needed. Laboratories are also moving from siloed molecular reports to clinically interpreted, evidence-tiered results that support tumor boards and treatment pathways. Regulatory expectations around analytical validity, clinical validity, laboratory quality systems, data security, and companion diagnostic claims are becoming more rigorous, while payers increasingly scrutinize clinical utility and outcome relevance. These shifts are pushing the industry toward standardized reporting, interoperable data systems, stronger evidence generation, and closer collaboration among oncologists, pathologists, laboratory directors, bioinformaticians, genetic counselors, and health systems.

Cumulative Impact of Artificial Intelligence on Tumor Profiling

Artificial intelligence is having a cumulative impact across cancer/tumor profiling by improving data interpretation, workflow efficiency, and multimodal decision support. In digital pathology, AI-enabled image analysis is being used to support tumor detection, grading, quantification of immune markers, spatial analysis, and quality control, while maintaining the need for expert pathologist oversight. In molecular profiling, machine learning methods help prioritize variants, detect complex genomic patterns, integrate copy number and structural alterations, and support interpretation of variants of uncertain significance when linked to curated knowledge bases and clinical evidence frameworks. AI is also accelerating biomarker discovery by integrating genomic, transcriptomic, proteomic, radiomic, pathology, and clinical outcome data. In liquid biopsy, computational methods are improving signal detection in low-fraction circulating tumor DNA samples, although pre-analytical controls and orthogonal validation remain critical. The most valuable applications are those embedded in validated laboratory workflows with transparent model performance, bias assessment, auditability, cybersecurity controls, and clinician-readable outputs. Industry leaders are increasingly focused on explainable AI, federated analytics, privacy-preserving data collaboration, and regulatory-ready documentation. The practical impact is not the replacement of specialists but the amplification of oncology teams' ability to process complex data, identify clinically relevant biomarkers, reduce turnaround friction, and support personalized cancer treatment decisions.

Key Regional Insights Across Global Cancer Profiling Adoption

Asia-Pacific is advancing rapidly as cancer/tumor profiling adoption expands across major oncology centers, supported by high cancer incidence, growing sequencing capacity, national precision medicine initiatives, and increased availability of targeted therapies. Japan, China, South Korea, India, and Australia are key contributors, with strong activity in lung cancer biomarkers, gastrointestinal cancers, breast cancer, liver cancer, and liquid biopsy research. Europe demonstrates strong momentum through harmonized clinical guidelines, high-quality pathology networks, national genomics programs, and increasing use of molecular tumor boards, although access still varies between Western, Southern, Central, and Eastern European health systems. North America remains a highly mature environment for cancer profiling due to established molecular pathology infrastructure, broad use of comprehensive genomic profiling in advanced cancers, strong clinical trial networks, and well-developed reimbursement pathways for selected biomarker tests. The United States drives much of the region's biomarker-guided oncology adoption, while Canada emphasizes provincial cancer programs, laboratory quality standards, and equitable access considerations. Latin America is progressing unevenly, with Brazil and Mexico leading regional activity but facing challenges related to reimbursement, laboratory distribution, specialist availability, and cross-border access to advanced testing. Africa is at an earlier stage of adoption, with cancer profiling concentrated in specialized urban centers and academic collaborations; key priorities include pathology capacity, sample logistics, workforce training, cancer registry strengthening, and affordable access to validated molecular diagnostics. The Middle East is investing in tertiary cancer centers, genomic medicine programs, and oncology infrastructure, particularly in high-income Gulf economies, while broader regional access remains constrained by workforce and reimbursement gaps.

Key Group Insights for Cancer/Tumor Profiling Markets

NATO countries overlap significantly with advanced European and North American healthcare systems, where cancer/tumor profiling is shaped by military and civilian medical research, health security priorities, data governance, and cross-border clinical collaboration, while adoption levels vary among member states based on funding, reimbursement, and laboratory infrastructure. G7 countries generally demonstrate advanced adoption of biomarker-driven oncology due to mature health systems, established laboratory accreditation, robust clinical research, and access to targeted and immuno-oncology therapies. BRICS economies represent a diverse but strategically important cancer profiling environment: China and India are expanding sequencing and oncology testing capacity at scale, Brazil and South Africa are building access through reference centers and public-private clinical networks, and Russia maintains specialized oncology and molecular diagnostic capabilities despite access and technology-transfer constraints. The European Union benefits from cross-country regulatory alignment, clinical guideline adoption, data protection frameworks, reference laboratory networks, and initiatives supporting access to comprehensive cancer care, while still managing differences in reimbursement and implementation across member states. ASEAN countries are increasing cancer profiling capacity through expanding oncology infrastructure, medical tourism hubs, academic collaborations, and gradual integration of molecular testing into tertiary care, although adoption differs substantially between Singapore, Malaysia, Thailand, Indonesia, the Philippines, and Vietnam. The GCC is emerging as a focused precision oncology adopter, supported by government investment in genomic medicine, tertiary cancer centers, and national health transformation strategies, with attention on hereditary cancer, lung cancer, breast cancer, and population genomics.

Key Country Insights in Cancer/Tumor Profiling

China is scaling cancer/tumor profiling through major hospital networks, domestic sequencing capabilities, and high clinical demand in lung, gastrointestinal, liver, and breast cancers. The United States is one of the most advanced countries for cancer profiling, driven by broad clinical use of next-generation sequencing, strong oncology guidelines, molecular tumor boards, companion diagnostics, and a large clinical trial ecosystem. Japan has a structured precision oncology environment, including comprehensive genomic profiling pathways and strong adoption of companion diagnostics. India is experiencing rising adoption in metropolitan cancer centers, with growth linked to increasing oncologist awareness, expanding laboratory services, and the need for cost-effective testing models. Germany maintains robust molecular diagnostics, pathology expertise, and clinical research capacity, supported by high standards for laboratory validation and specialist oncology care. The United Kingdom has advanced national genomics infrastructure, strong pathology networks, and increasing integration of genomic testing into cancer care pathways. Australia combines high-quality cancer care, national research networks, and adoption of molecular testing in specialized centers, with attention to equitable access across geographically dispersed populations. France has long-standing molecular testing networks and national cancer planning experience, supporting biomarker testing across key tumor types. South Korea is a technologically advanced environment with strong hospital-based precision oncology programs, sequencing capability, and digital health infrastructure supporting biomarker-driven care. Italy and Spain show strong adoption in major oncology centers, particularly for lung, breast, colorectal, ovarian, and melanoma profiling, with national and regional reimbursement structures influencing consistency. Canada has well-established cancer care institutions and provincial testing programs, with ongoing emphasis on consistent access, reimbursement alignment, and laboratory quality. Russia has specialized oncology institutions and molecular diagnostic expertise, though access may vary by region and healthcare funding pathway. Brazil leads much of Latin America in oncology research and advanced diagnostics adoption, especially in private and academic centers, but regional disparities remain significant. Mexico is expanding molecular oncology capacity in leading urban centers, while affordability and insurance coverage influence access. Spain continues to strengthen precision oncology through specialist cancer networks, pathology capabilities, and guideline-driven biomarker testing across high-priority tumor types.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated cancer/tumor profiling solutions that demonstrate analytical accuracy, reproducibility, actionable reporting, and clear links to treatment decisions. A strong strategy should include integrated tissue and liquid biopsy workflows, robust pre-analytical controls, rapid turnaround times, and evidence-based variant interpretation aligned with recognized oncology reporting frameworks. Organizations should invest in interoperable data platforms that connect laboratory information systems, pathology images, genomic files, electronic health records, and clinical trial matching tools while maintaining privacy, cybersecurity, and consent controls. Partnerships with cancer centers, academic networks, pathology groups, and public health programs can improve evidence generation and real-world clinical utility. Leaders should also address access barriers by developing tiered testing pathways, regional reference laboratory models, clinician education programs, and payer engagement strategies based on patient outcomes rather than test volume. AI adoption should be governed through transparent validation, bias monitoring, human oversight, and ongoing performance audits. To remain competitive, stakeholders should focus on scalable bioinformatics, quality management, regulatory readiness, multidisciplinary tumor board support, and patient-centered reporting that helps oncologists translate complex biomarker information into timely therapeutic action.

Research Methodology

This executive summary is developed through a structured secondary research approach using verified public-domain and industry-recognized sources, including oncology clinical guidelines, regulatory publications, peer-reviewed literature, cancer registry data, public health agency resources, laboratory medicine standards, and precision oncology policy documents. The methodology emphasizes evidence triangulation across clinical practice recommendations, diagnostic technology adoption patterns, biomarker utility studies, regional healthcare infrastructure indicators, and publicly available national cancer control initiatives. Insights are screened to avoid unsupported claims and exclude market sizing, forecasting, and company-specific positioning. Regional, group, and country assessments are synthesized from documented healthcare infrastructure, cancer care maturity, reimbursement context, genomic medicine initiatives, and adoption of molecular diagnostics in oncology. The analysis focuses on qualitative strategic intelligence, clinical relevance, technology transformation, and implementation barriers rather than revenue estimates. Key themes are validated through consistency across multiple credible sources, with attention to regulatory status, laboratory quality expectations, clinical utility, data governance, and access equity.

Conclusion

Cancer/tumor profiling is redefining oncology by linking molecular and cellular tumor characteristics to diagnosis, prognosis, therapy selection, resistance monitoring, and clinical trial eligibility. The field is advancing from narrow biomarker testing toward integrated precision oncology ecosystems that combine tissue analysis, liquid biopsy, digital pathology, bioinformatics, and AI-supported interpretation. Adoption is strongest where clinical guidelines, reimbursement, laboratory quality systems, specialist networks, and targeted therapy access are aligned, while emerging regions continue to prioritize infrastructure, affordability, and workforce development. Artificial intelligence, multimodal data integration, and standardized reporting will continue to improve the usefulness of tumor profiling, provided that validation, transparency, and equity remain central. For healthcare systems, laboratories, and technology providers, the most important opportunity is to make cancer profiling clinically actionable, operationally scalable, and accessible to more patients across diverse care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cancer/Tumor Profiling Market, by Product Type

  • 7.1. Introduction
  • 7.2. Consumables Reagents
    • 7.2.1. Antibodies
    • 7.2.2. PCR Reagents
    • 7.2.3. Probes
    • 7.2.4. Sequencing Reagents
  • 7.3. Instruments
    • 7.3.1. Fluorescence Microscopes
    • 7.3.2. Mass Spectrometers
    • 7.3.3. Microarray Scanners
    • 7.3.4. PCR Instruments
    • 7.3.5. Sequencers
  • 7.4. Software & Services
    • 7.4.1. Bioinformatics Software
    • 7.4.2. Cloud Platforms
    • 7.4.3. Consultation Services
    • 7.4.4. Data Management Systems

8. Cancer/Tumor Profiling Market, by Technology

  • 8.1. Introduction
  • 8.2. Fluorescence In Situ Hybridization & Cytogenetics
  • 8.3. Immunohistochemistry
  • 8.4. Microarray Technologies
  • 8.5. Next Generation Sequencing

9. Cancer/Tumor Profiling Market, by Cancer Type

  • 9.1. Introduction
  • 9.2. Tumors
    • 9.2.1. Breast Cancer
    • 9.2.2. Lung Cancer
    • 9.2.3. Colorectal Cancer
    • 9.2.4. Prostate Cancer
  • 9.3. Hematologic Malignancies
    • 9.3.1. Leukemia
    • 9.3.2. Lymphoma
    • 9.3.3. Multiple Myeloma

10. Cancer/Tumor Profiling Market, by Sample Type

  • 10.1. Introduction
  • 10.2. Tissue
  • 10.3. Blood
  • 10.4. Bone Marrow

11. Cancer/Tumor Profiling Market, by Clinical Application

  • 11.1. Introduction
  • 11.2. Prognosis
  • 11.3. Therapy Selection
  • 11.4. Monitoring & Surveillance
    • 11.4.1. Treatment Response Monitoring
    • 11.4.2. Recurrence Monitoring
    • 11.4.3. Minimal Residual Disease Monitoring
  • 11.5. Screening & Risk Assessment

12. Cancer/Tumor Profiling Market, by End User

  • 12.1. Introduction
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals & Clinics
  • 12.4. Pharma & Biopharma Companies
  • 12.5. Research & Academic Institutes

13. Cancer/Tumor Profiling Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Cancer/Tumor Profiling Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Cancer/Tumor Profiling Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. 4basecare Onco Solutions Private Limited
  • 17.2. ACT Genomics Co., Ltd. by Prenetics Global Limited
  • 17.3. Agendia, Inc.
  • 17.4. Agilent Technologies, Inc.
  • 17.5. BostonGene Corporation
  • 17.6. Caris Life Sciences
  • 17.7. Exact Sciences Corporation
  • 17.8. F. Hoffmann-La Roche Ltd.
  • 17.9. GENINUS Inc.
  • 17.10. GenScript Biotech Corporation
  • 17.11. Guardant Health, Inc.
  • 17.12. Hologic, Inc.
  • 17.13. HTG Molecular Diagnostics, Inc.
  • 17.14. Illumina, Inc.
  • 17.15. IMBdx, Inc.
  • 17.16. Laboratory Corporation of America Holdings
  • 17.17. Lucence Health, Inc.
  • 17.18. Merck KGaA
  • 17.19. NanoString Technologies, Inc.
  • 17.20. Neogenomics, Inc.
  • 17.21. Nonacus Limited
  • 17.22. OncoDNA S.A.
  • 17.23. Oncompass Medicine Hungary Kft.
  • 17.24. Paragon Genomics, Inc.
  • 17.25. Personalis, Inc.
  • 17.26. Perthera, Inc.
  • 17.27. Predictive Oncology Inc.
  • 17.28. Strand Life Sciences
  • 17.29. Sysmex Corporation
  • 17.30. Takara Bio Inc.
  • 17.31. Tempus Labs Inc.
  • 17.32. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER/TUMOR PROFILING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CANCER/TUMOR PROFILING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CANCER/TUMOR PROFILING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CANCER/TUMOR PROFILING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CANCER/TUMOR PROFILING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL CANCER/TUMOR PROFILING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER/TUMOR PROFILING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONSUMABLES REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONSUMABLES REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CONSUMABLES REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PCR REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PCR REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PCR REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROBES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PROBES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROBES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SEQUENCING REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SEQUENCING REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SEQUENCING REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FLUORESCENCE MICROSCOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FLUORESCENCE MICROSCOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FLUORESCENCE MICROSCOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MASS SPECTROMETERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MASS SPECTROMETERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MASS SPECTROMETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MICROARRAY SCANNERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MICROARRAY SCANNERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MICROARRAY SCANNERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PCR INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PCR INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PCR INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SEQUENCERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SEQUENCERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SEQUENCERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOINFORMATICS SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOINFORMATICS SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOINFORMATICS SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CLOUD PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CLOUD PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CLOUD PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CONSULTATION SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONSULTATION SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CONSULTATION SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DATA MANAGEMENT SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DATA MANAGEMENT SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DATA MANAGEMENT SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION & CYTOGENETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION & CYTOGENETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION & CYTOGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MICROARRAY TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MICROARRAY TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MICROARRAY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TISSUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TISSUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL TISSUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BONE MARROW MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BONE MARROW MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BONE MARROW MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PROGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PROGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PROGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL THERAPY SELECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL THERAPY SELECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL THERAPY SELECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MONITORING & SURVEILLANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MONITORING & SURVEILLANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MONITORING & SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL TREATMENT RESPONSE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TREATMENT RESPONSE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL TREATMENT RESPONSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MINIMAL RESIDUAL DISEASE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL MINIMAL RESIDUAL DISEASE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL MINIMAL RESIDUAL DISEASE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL SCREENING & RISK ASSESSMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL SCREENING & RISK ASSESSMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL SCREENING & RISK ASSESSMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PHARMA & BIOPHARMA COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PHARMA & BIOPHARMA COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PHARMA & BIOPHARMA COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY TUMORS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY MONITORING & SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE CANCER/TUMOR PROFILING MARKET SIZE, BY TUMORS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE CANCER/TUMOR PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE CANCER/TUMOR PROFILING MARKET SIZE, BY MONITORING & SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY TUMORS, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY MONITORING & SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY TUMORS, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY MONITORING & SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TUMORS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY MONITORING & SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST CANCER/TUMOR PROFILING MARKET SIZE, BY TUMORS, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST CANCER/TUMOR PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST CANCER/TUMOR PROFILING MARKET SIZE, BY MONITORING & SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. NATO CANCER/TUMOR PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. NATO CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 222. NATO CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 223. NATO CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. NATO CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. NATO CANCER/TUMOR PROFILING MARKET SIZE, BY TUMORS, 2018-2032 (USD MILLION)
  • TABLE 226. NATO CANCER/TUMOR PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 227. NATO CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. NATO CANCER/TUMOR PROFILING MARKET SIZE, BY MONITORING & SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 230. NATO CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. G7 CANCER/TUMOR PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. G7 CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. G7 CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 234. G7 CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 235. G7 CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 236. G7 CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. G7 CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. G7 CANCER/TUMOR PROFILING MARKET SIZE, BY TUMORS, 2018-2032 (USD MILLION)
  • TABLE 239. G7 CANCER/TUMOR PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 240. G7 CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. G7 CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. G7 CANCER/TUMOR PROFILING MARKET SIZE, BY MONITORING & SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 243. G7 CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS CANCER/TUMOR PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS CANCER/TUMOR PROFILING MARKET SIZE, BY TUMORS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS CANCER/TUMOR PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS CANCER/TUMOR PROFILING MARKET SIZE, BY MONITORING & SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION CANCER/TUMOR PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION CANCER/TUMOR PROFILING MARKET SIZE, BY TUMORS, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION CANCER/TUMOR PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION CANCER/TUMOR PROFILING MARKET SIZE, BY MONITORING & SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN CANCER/TUMOR PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN CANCER/TUMOR PROFILING MARKET SIZE, BY TUMORS, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN CANCER/TUMOR PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN CANCER/TUMOR PROFILING MARKET SIZE, BY MONITORING & SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. GCC CANCER/TUMOR PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 284. GCC CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. GCC CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 286. GCC CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 287. GCC CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 288. GCC CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. GCC CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. GCC CANCER/TUMOR PROFILING MARKET SIZE, BY TUMORS, 2018-2032 (USD MILLION)
  • TABLE 291. GCC CANCER/TUMOR PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 292. GCC CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. GCC CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 294. GCC CANCER/TUMOR PROFILING MARKET SIZE, BY MONITORING & SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 295. GCC CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA CANCER/TUMOR PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY TUMORS, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY MONITORING & SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TUMORS, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY MONITORING & SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 323. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 326. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 327. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 328. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 329. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY TUMORS, 2018-2032 (USD MILLION)
  • TABLE 331. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 332. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 334. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY MONITORING & SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 335. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 336. INDIA CANCER/TUMOR PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 337. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 339. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 340. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 341. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 342. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 343. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY TUMORS, 2018-2032 (USD MILLION)
  • TABLE 344. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 345. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 347. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY MONITORING & SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 348. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 349. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 350. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 351. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 352. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 353. GERMANY CANCER/TUMOR